Barely a year after the U.S. FDA shackled Abeona Therapeutics Inc.’s cell-based gene therapy with a complete response letter, the agency has approved it for treating a rare and genetic skin disease.

In a phase 3 trial, 81% of wounds treated with autologous cell sheet-based gene therapy showed ≥ 50% healing at 6 months, ...

A cucumber is a nutritious fruit with a high water content. It's great at preventing dehydration, among other health benefits ...

Carnegie Mellon researchers have used FRESH 3D bioprinting to create the first collagen-based microphysiologic systems, ...

Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...

The condition, recessive dystrophic epidermolysis bullosa, causes chronic wounds and has an 84% mortality rate by age 40.

This discovery is important because diabetic neuropathy is more than just a painful condition. It can cause serious long-term ...

A new study has found that a group of diabetes drugs called SGLT2 inhibitors may increase the risk of a rare but dangerous ...

While more research is needed to verify which fibroblast subtype is harmful and which is helpful, the results here show that ...

First wearable device to monitor health by detecting gases emitted from and absorbed through the skin. Researchers at ...

Your skin can tell you a lot about your health. Sometimes, small changes like a new spot, rash, or strange color could be a ...

eye problems, known as diabetic retinopathy, and kidney issues, increasing the risk of chronic and end-stage kidney disease. Additionally, high blood sugar levels can also impact the skin ...